ArticleInternational ophthalmology2021
Risk factors for progression following corneal collagen crosslinking in keratoconus.
Article in International ophthalmology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- One-Year Visual, Refractive, Tomographic, and Aberrometric Outcomes of Repeat Corneal Collagen Crosslinking in Eyes with Progressive Keratoconus.Beyoglu eye journal · 2026Article
- The Effects of Eye Rubbing on Corneal Topography and Biomechanics in Children With Allergic Conjunctivitis.Translational vision science & technology · 2025Observational
- Machine learning-based progress prediction in accelerated cross-linking for Keratoconus.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Article
- Demographic and topographic findings suggesting poor response to crosslinking-iontophoresis in patients with progressive keratoconus.International ophthalmology · 2025Article
- Individual Risk Assessment and Prognostication of Outcomes After Corneal Cross-Linking.Journal of ophthalmology · 2025Article
- Corneal surface changes after stromal lenticule addition keratoplasty combined with cross-linking for severe keratoconus.International journal of ophthalmology · 2025Article
- Digital transformation of care for keratoconus patients: ML modeling structural outcomes of corneal collagen cross-linking.Frontiers in medicine · 2025Article
- Outcomes of accelerated corneal cross-linking for pediatric and adult keratoconus: a comparative study.International ophthalmology · 2024Article
- Systemic Associations with Keratoconus.Life (Basel, Switzerland) · 2023Review
- Development and validation to predict visual acuity and keratometry two years after corneal crosslinking with progressive keratoconus by machine learning.Frontiers in medicine · 2023Article
- Intraocular lens power calculation changes before and after isotonic collagen cross-linking in keratoconus patients.Indian journal of ophthalmology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess risk factors for progression following corneal collagen crosslinking (CXL) in eyes with keratoconus.
methodsCharts of patients who developed progression following conventional CXL treatment (Dresden protocol) were retrospectively evaluated in two centers (Center 1 and Center 2). 871 eyes of a total of 676 patients were analyzed. Progression was defined as > 1 diopter (D) increase in maximum keratometry (Kmax) readings compared to baseline.
resultsProgression was noted in 20 eyes of 20 patients (progression rate 3%). The mean age of the patients was 17.65 ± 5.76 (11-34)-years-old, and the mean follow-up following CXL was 36.70 ± 25.72 (12-84)-months-old. The gender distribution was 13 (65%) females and seven (35%) males. Four eyes (20%) had mild, 13 eyes (65%) had moderate, and three eyes (15%) had severe keratoconus at baseline. Fifteen eyes (75%) had allergic conjunctivitis, and 20 eyes (100%) reported eye-rubbing. Cone location was central in 17 (85%) eyes, and peripheral in 3 (15%) eyes. A mean of 2.21 ± 1.30 D (1.00-5.30 D) steepening was determined at Kmax 6 to 82 months following CXL treatment.
conclusionsProgression rate was found to be higher in the patients under the age of 17 years, female gender, allergic conjunctivitis, high preoperative Kmax (> 57 D), thin corneas (< 430 µm). The majority of progressive patients were central cone and moderate keratoconus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.